MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Operating Income 2011-2026 | RMTI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.67 M | -16.8 M | -30.3 M | -28.4 M | -34.5 M | -32.4 M | -25.9 M | -20.2 M | -15.1 M | -17.6 M | -47.1 M | -54.3 M | -21.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.67 M | -54.3 M | -27 M |
Quarterly Operating Income Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.58 M | -1.35 M | - | 1.94 M | 515 K | -1.32 M | - | -1.74 M | -2.96 M | -1.43 M | - | -3.71 M | -4.48 M | -6.63 M | - | -6.97 M | -7.82 M | -7.18 M | - | -6.69 M | -5.6 M | -8.06 M | - | -7.94 M | -10.4 M | -8.81 M | - | -5 M | -12.3 M | -5.72 M | -9.22 M | -5.03 M | -6.72 M | -4.96 M | -5.26 M | -4.75 M | -5.59 M | -4.61 M | -6.06 M | -2.57 M | -2.65 M | -3.81 M | -5.02 M | -3.13 M | -2.38 M | -7.03 M | -7.53 M | -12.4 M | -11.8 M | -15.4 M | -13.7 M | -17.9 M | -12 M | -10.7 M | -8.96 M | -5.12 M | -4.62 M | -3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 M | -17.9 M | -6.22 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.14 | -1.72 % | $ 123 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.22 | -0.94 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.36 | 1.64 % | $ 633 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 5.18 | - | $ 682 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.88 | -0.73 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.55 | 0.05 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-34.4 M | $ 6.65 | -0.3 % | $ 412 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 49.0 | -2.04 % | $ 1.6 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.64 | 0.64 % | $ 4.52 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.21 | -9.02 % | $ 21.1 M |  China |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.68 | -1.18 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 6.95 | -0.57 % | $ 2.54 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.14 | -1.38 % | $ 289 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.98 | 0.51 % | $ 56 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.66 | 0.61 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 13.92 | -0.14 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | $ 0.45 | -1.28 % | $ 7.13 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.83 | 6.62 % | $ 145 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.35 | -0.37 % | $ 5.82 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 9.07 | -1.41 % | $ 644 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.64 | -1.05 % | $ 230 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.63 | 4.43 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 9.03 | 0.11 % | $ 5.58 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.63 | -0.61 % | $ 17 M | USA |
 |
Viatris
VTRS
|
1.61 B | $ 12.45 | -0.72 % | $ 15.1 B | USA |